Shorts believe Fusilev sales are going to zero!!!! I think this result verifies what Raj has said all along. Fusilev revenue is sustainable at some level. $44M a quarter is ok with me.. $175M annually makes this company viable for a long time. Grow the other drugs!! Develop the pipeline!!! Eventually this short money will be dead money because Spectrum is NOT GOING TO ZERO!!!